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been studied as extensively as gastric bypass.
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Methods: Literature search of Medline OVID, CINHAL, and WebScience using the keywords “gastric
banding”, “diabetes”, “impaired glucose tolerance”, and “glucose control”.
Results: All studies confirmed LAGB is effective in weight loss and glycemic control with a majority of
patients achieving diabetes resolution one year post surgery.
Conclusion: LAGB should be considered as a treatment for obese diabetic patients. Preliminary evidence
suggests consideration for pre-diabetics and patients below the NIH recommended guidelines of BMI ≥40 or
≥ 35 with co-morbidities should also be considered as a preventative measure.
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Abstract 
Background:  Obesity, and therefore diabetes, is an ever growing problem in worldwide 
healthcare.  As weight loss is critical in controlling blood sugar levels, more 
patients are turning to bariatric surgery after failing conventional weight loss 
methods.  Gastric bypass, as the most commonly performed bariatric surgery, has 
been shown to be effective in glycemic control and even diabetes resolution.  
Laparoscopic adjustable gastric banding, however, is becoming more prevalent 
and its effects on diabetes and serum glucose levels have not been studied as 
extensively as gastric bypass.   
Hypothesis:  LAGB is an effective method of glycemic control in obese, diabetic 
patients. 
Study Design:  Exhaustive search of available medical literature. 
Methods: Literature search of Medline OVID, CINHAL, and WebScience using the 
keywords “gastric banding”, “diabetes”, “impaired glucose tolerance”, and 
“glucose control”. 
Results:  All studies confirmed LAGB is effective in weight loss and glycemic control 
with a majority of patients achieving diabetes resolution one year post surgery.   
Conclusion: LAGB should be considered as a treatment for obese diabetic patients.  
Preliminary evidence suggests consideration for pre-diabetics and patients below 
the NIH recommended guidelines of BMI ≥40 or ≥ 35 with co-morbidities should 
also be considered as a preventative measure.    
Keywords: Laparoscopic adjustable gastric banding, diabetes, glycemic control.   
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Effectiveness of LAGB on Obese Diabetic Patients 
Introduction 
 The World Health Organization estimates that by the year 2015 there will be 2.3 
billion overweight and 700 million obese adults in the world1.  As it is an independent 
risk factor for Type 2 Diabetes Mellitus (T2DM) and is associated with other co-
morbidities such as hypertension, osteoarthritis, GERD, and depression, obesity has 
become a major health problem in American society2, 3.  With over half of diabetics being 
obese and approximately 9% having a body mass index (BMI) of >40, or severely obese, 
this population requires special consideration3, 4.  In fact, according to Brancatisano et al., 
obesity combined with T2DM can increase mortality by 45-55% in a five year period3.   
First line treatment is, of course, weight loss which has been shown to be highly 
effective in managing glucose levels and in increasing insulin sensitivity5.  Newly 
diagnosed patients are counseled by clinicians on diet and in restricting caloric intake to 
reduce fasting blood sugars (FBS), thereby preventing complications.  For most patients, 
this means drastic changes in eating and exercise habits.  Observational experience and 
research trials have demonstrated that continued weight loss or long term maintenance of 
weight loss is extremely difficult outside a clinically structured program with patient 
accountability6 and even those have only modest success7.  In many cases, patients are 
not only fighting physiological accommodations of chronic overeating but also 
psychologically compelling impetus.   
Therefore, in extreme cases, additional methods must be used to acquire desired 
results.  A treatment increasing in popularity for weight loss is bariatric surgery.  Multiple 
studies on this topic have demonstrated positive effects on quality of life and diabetic 
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outcomes8.  However, there are two different procedural methods of bariatric surgery: 
malapsorptive, such as the Roux-en-Y gastric bypass, and restrictive, such as 
laparoscopic adjustable gastric banding.  Most studies up to this point have looked at 
gastric bypass or bypass and banding combined, only a few have studied banding alone.   
The Roux-en-Y procedure is the oldest FDA approved method and is currently the 
most commonly performed in the US9.  Here, the surgeon staples a portion of the 
stomach then reroutes the small intestine to bypass the first several centimeters.  This 
reduces the size of the stomach, limiting the amount of possible food intake, and 
decreases absorption once the food is processed10.   
Laparoscopic adjustable gastric banding (LAGB) was approved in 2001 by the 
Food and Drug Administration (FDA), but was practiced in Europe several years 
earlier11.  In this procedure, the surgeon creates 3-6, 3cm incisions in the patient’s 
abdomen to insert laparoscopic equipment.  An inflatable band is then placed around the 
proximal antrum of the stomach.  The band can be inflated or deflated in a clinic setting, 
as desired, to restrict food intake10.   
Statistically, the Roux-en-Y is the most effective method of producing sustained 
weight loss10.  However, it carries a greater risk of morbidity and mortality than LAGB 
(2.6% vs. 0%) 11and is associated with serious nutritional deficiencies due to the 
decreased absorption.  While it can be performed laparoscopically, the Roux-en-Y 
procedure is occasionally converted to an incisional surgery.  LAGB, on the other hand, 
is rarely converted and is a reversible procedure12.  Logistics are also in favor of LAGB.  
Generally, gastric banding means a shorter time on the operating table as well as a 
quicker discharge11.  For these reasons, LAGB is the most commonly performed bariatric 
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surgery worldwide and is rapidly replacing gastric bypass as the favored surgery in the 
U.S13.  However, as far as this researcher could gather, there is no systematic review of 
LAGB alone and its effects on diabetes.   
As FBS and Hemoglobin A1c (HbA1c) are the measures used in a clinic setting to 
diagnose or monitor T2DM, these will be used as the objective data to determine if 
LAGB is effective in controlling diabetes in obese patients.  The results of this research 
could change personal recommendations and treatments to patients in primary care 
settings.   
Methods 
 CINHAL, OVID and WebScience were searched using the keywords “gastric 
banding”, “diabetes”, “impaired glucose tolerance”, and “glucose control”.  Some articles 
were also selected from the reference sections of key articles.  Each article was critically 
appraised.   
 Inclusion criteria included:  any primary article directly addressing the effects of 
laparoscopic adjustable gastric banding performed on obese or morbidly obese human 
patients with diabetes.  As FBS and HbA1c are the primary measures of glycemic 
control, the articles were also required to have these numbers in the follow up data at 
least one year post operation in order to address long term effects.  Exclusion criteria 
included:  abstracts only, an article not being written in English, or being older than 10 
years, or review articles.  One article was excluded due to data being reported in graph 
form without clear numerical values assigned to data points.  One article scored less than 
3 out of 5 on the therapy analysis validation form and therefore was not used. 
Results 
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 Dixon and O’Brien studied 50 severely obese (BMI > 35) diabetic patients who 
had attempted other methods of weight reduction for at least 5 years before presenting to 
a surgeon for LAGB.  One year later, BMI dropped from 48.2 to 38.7 with a % excess 
weight loss (%EWL) of 38%.  Fasting plasma glucose decreased from 169.2 mg/dL to 
111.6 mg/dL.  HbA1c levels also declined from 7.8 to 6.2%.  Dixon and O’Brien did not 
record numerical data for the number of patients able to discontinue their medications but 
did note a “major reduction” in oral hypoglycemic use14.   
Six years later, Dixon et al. expounded on their findings from the previous study 
and created the only randomized control trial of obese, recently diagnosed (≤ 5 years), 
diabetic patients, contrasting LAGB with conventional therapy.   Conventional therapy 
consisted of individually structured lifestyle modification programs (diet and exercise), 
medical therapies determined by an experienced diabetologist, and regular six week 
visits.  All reported data was acquired two years post-operation.  This group had the 
lowest preoperative average BMI of all six studies at 37 due to the inclusion of 13/60 
patients with a BMI less than 35.  These 13 were equally distributed between the surgical 
and control groups.  The surgical arm of this study achieved an average of 62.5% EWL.  
HbA1c baseline average was 7.8%, two years later it was 6.0%.  80% of participants 
reached targeted HbA1c levels which was a statistically significant improvement from 
baseline.  Plasma glucose decreased by 51.2 mg/dL from 156.7 mg/dL to 105.6 mg/dL 
(see Table 1).  Metformin and insulin use also decreased in that same time period15.    
 Brancatisano et al. prospectively studied 78 obese diabetics who fit the NIH 
requirements for bariatric surgery.  This study also reported significant decreases in BMI, 
HbA1c and glucose in the 12.5 months post surgery.  T2DM patients demonstrated 38% 
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EWL and decreased BMI from 47 to 38.  Average HbA1c went from 8.0 to 6.1%.  Serum 
glucose fell from 172.8 to 102.6 mg/dL.  Here too, a significant percentage of the 
population was able to discontinue or reduce oral hypoglycemic and insulin use3.   
 Ponce et al. excluded diabetics not on medications from their study in order to 
directly research effects of LAGB on medication use.  BMI decreased from 48.7 to 38.2 
at twelve months and to 38.4 at 24 months.  %EWL measured 39% at 12 months and 
52.6% at 24 months.  HbA1c measured 7.25% then fell to 5.87% at one year and 5.58% 
at two years.  Serum glucose levels were not reported.  At the one year data point, 66% of 
the 53 T2DM patients were off all medications.  By the second year, 80% had 
discontinued4.   
 In 2005, Pontiroli et al. published a study specifically oriented towards LAGB in 
the morbidly obese (BMI > 40) and its influence on diabetes remission.  In it, they 
reported a BMI decrease from 48.3 to 41.9 at one year and 41.1 at two years with data 
continuing up to four years.  HbA1c was reduced from 9.4% to 5.9% in the first year and 
by the fourth year it was down to 5.3%.  Serum glucose levels and %EWL were not 
reported12.   
 Singhal et al. had the largest study group with 122 obese diabetic subjects 
undergoing LAGB.  Changes in BMI were not reported but %EWL at one year was 
34.3%.  FBS dropped from 163.8 to 124.2 mg/dL.  HbA1c changed from 8.2 to 7.4% and 
all post surgical values were considered statistically significant.  This article did report on 
the number of patients able to discontinue or decrease medications, however, the data 
was broken down into individual drug statistics.  With patients on multiple therapies at 
one time, it is impossible to determine the total percentage of subjects discontinuing all 
 12 
medications.   However, each individual drug was decreased or discontinued to a 
statistically significant level16.  
Discussion 
 Only studies reporting data at least one year post surgery were included in this 
analysis.  While there are undeniable benefits to short term glycemic improvements, 
diabetes is a chronic illness requiring constant monitoring.  A treatment capable of 
controlling FBS on a long term basis is essential.   
 Lifestyle modifications, such as diet and exercise, are first line in prevention and 
control of T2DM.  Barnard et al. contrasted an American Diabetes Association (ADA) 
recommended diet vs. a vegan diet for glycemic control and reported a 0.14% and 0.34% 
decrease in HbA1c respectively in a 74 week period17.  Other studies report decreased 
insulin use or even discontinuation in a majority of their diet therapy patients18.  Non 
medical, non surgical methods can work.   
However, all diet studies required extreme changes in subjects’ eating habits and 
strict control of fiber, carbohydrate, and animal fat intake.  The majority of studies 
consisted of regular interventional groups lead by physicians, dieticians, and/or cooking 
instructors17, 19.  In many cases they included structured exercise plans as well.  To expect 
the average person to follow such a rigorous regimen without support and accountability 
is unreasonable.  In fact, Meneghini states that 95% of patients not involved “in a 
prevention research study are unable to achieve and maintain any significant weight loss 
over time”10.   
When compared to surgical therapies, diet alone falls short of enabling patients to 
reach target BMIs and therefore FBS or HbA1c.  In Dixon et al.’s study comparing 
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LAGB to diet therapy, not only did patients lose a significantly lower percentage of 
excess weight than their surgical counterparts (1.4% vs. 20%) but, as time passed, the 
patients were unable to maintain their weight loss15.  Pontiroli et al., in 2002 reported 
diet-treated patients as obtaining a lower BMI than LAGB patients at six and nine months 
but by month twelve, average BMI had returned almost to baseline for the dietary group 
while LAGB treated subjects continued to lose weight12.  Modest weight reduction is 
difficult to obtain with nonsurgical methods14.  Therefore, as glycemic control is directly 
linked with %EWL3, 11, 15, if unable to maintain weight loss, diabetic patients will never 
attain remission.   
Medications are second line for T2DM treatment.  However, as with all chronic 
diseases, there is physical deterioration over time.  In diabetics, pancreatic function 
gradually fails and glycemic control becomes more difficult14.  In a study published in 
1999, Turner et al. showed that oral hypoglycemic medication, when used as 
monotherapy, would improve the HbA1c of diabetic patients 2-3 times better than diet 
alone.  After three years, only 50% of these patients could sustain a HbA1c in normal 
range (<7.0%) on monotherapy and by nine years, only 25% could maintain a normal 
HbA1c.  As the disease progresses, multiple therapies become critical to achieving target 
levels.  Eventually, a patient can be taking several oral hypoglycemics and insulin but 
remains hyperglycemic20.   
 With that in mind, LAGB proves itself to be a highly effective method of long 
term diabetes control.  The studies analyzed here demonstrate substantial decrease and 
long term maintenance of fasting serum glucose levels and HbA1c at several years post 
LAGB surgery.  The Swedish Obese Subjects Study has shown bariatric surgery, 
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including LAGB, to be effective in weight reduction for at least ten years21.  
Theoretically, the sequelae of this weight loss continue to be effective as well.   
Diabetes remission in three of the five articles was defined as exceptional 
glycemic control with HbA1c below 6.0% and cessation of all medications3, 4, 15.  Dixon 
et al.’s 2008 study had a 76% remission rate at two years15.  Ponce et al. reported 
remission increasing with time- 66% at one year, 80% at two years and, of the 3 patients 
who continued follow up to three years, 100% were in remission4.  Brancatisano et al. 
reported a 43% complete remission of diabetes after 12.5 months3.  Dixon and O’Brien’s 
initial 2002 study defined remission as exceptional glycemic control but omitted the 
discontinuation of medication criterion. This study reported a 64% remission rate at one 
year14.  Pontiroli and associates did not define remission but reported it at 45%, again at 
one year22.  Singhal et al. did not mention remission specifically but did report 93% of 
patients significantly reducing FBS and 75% improving HbA1c at the end of one year16.   
If reporting the number of patients able to decrease their medications plus the 
number of patients who discontinued completely, the percentages go up significantly.  In 
some cases, it doubles3, 22.  Even studies not directly measuring FBS or HbA1c support 
these findings by reporting a decrease in oral hypoglycemic use, with a significant 
percentage of patients discontinuing medications entirely23-26.   
 With bariatric surgery being the only effective, long term treatment for diabetes in 
a majority of patients, it should be considered more often by primary care clinicians for 
obese diabetics.  Several investigators have noted diabetics tend to lose less weight than 
non diabetics3, 4, 14, making their ability to control FBS without surgical intervention even 
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less likely.  Therefore, LAGB, as the preferred method of bariatric surgery, is a logical 
treatment option for these patients.   
 One interesting incidental finding noted in several studies is that the time from 
diagnosis to treatment seems to make a difference in patients’ remission rates.  
Brancatisano et al. reported a direct correlation linking the interval between T2DM 
diagnosis and surgical treatment to the likelihood of remission.  73% of LAGB patients 
who had been diagnosed less than five years had resolution compared to 27% of patients 
who had had T2DM for more than five years.  According to this, if treated within five 
years of diagnosis, a patient is 6.5 times more likely to go into remission3.  Ponce et al. in 
2004 and Dixon and O’Brien in 2002 support this finding4, 14, creating a strong argument 
for prompt surgical intervention in morbidly obese T2DM patients.   
 Preliminary studies indicate that not only is LAGB capable of causing remission 
in diabetics but it also prevents the development of diabetes in obese patients2, 14, 27.  
Therefore, as LAGB seems to provide effective preventative treatment, clinicians may 
want to consider this therapy earlier than guidelines recommend.  Current NIH guidelines 
for bariatric surgery are patients with a BMI ≥  40 or a BMI ≥ 35 with obesity related co-
morbidities, including diabetes.  In order to challenge these recommendations, O’Brien et 
al. created a randomized control study on diabetic patients with a BMI of 30-35 kg/m2.  
Once again, LAGB patients demonstrated a significant decrease in excess weight and 
superior glycemic control over medically managed patients7. 
If LAGB can prevent a chronic disease and improve overall quality of life, the 
topic of when bariatric surgery is performed should be readdressed.  Although NIH 
criteria for bariatric surgery are set based on a risk to benefit ratio, with LAGB 
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decreasing the mortality rate established by gastric bypass and the obvious preventative 
and curative benefits of bariatric surgery in obese diabetic patients with co-morbidities, 
these criteria should be reconsidered in select patients.   
Conclusion 
 LAGB is an effective method of long term diabetic control.  With the strong 
evidence towards remission and prevention of diabetes, primary care clinicians should 
consider LAGB during treatment of obese patients.  
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